LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Home・Elenco Azioni・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Chiusa

SettoreSettore sanitario

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

Massimo

Raccomandazioni
By TipRanks
Raccomandazioni	Neutrale
Previsioni per 12 mesi	-0.05% downside

Notizie sul Sentiment di mercato

By Acuity

25%

75%

67 / 349 Classifica in Healthcare

Mirati Therapeutics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

27 mar 2026, 17:33 UTC

Principali Notizie su Eventi

ECB Should Not Rush Its Response to Iran Conflict, Says Schnabel -- Update

27 mar 2026, 17:00 UTC

Principali Notizie su Eventi

ECB Shouldn't Rush Its Response to Iran Conflict, Schnabel Says

27 mar 2026, 16:03 UTC

Principali Notizie su Eventi

Fertilizer Maker Yara Warns Farmers Are Being Squeezed by Price Surge Amid War -- Commodities Roundup

27 mar 2026, 14:50 UTC

I principali Market Mover

Cybersecurity Stocks Fall on Leak About New Claude Model's Cyber Capabilities

27 mar 2026, 14:37 UTC

Acquisizioni, Fusioni, Takeovers

Nestle's Water Business Stake Sale Could Value Unit at Around $5.76 billion, FT Says, Citing Sources

27 mar 2026, 14:29 UTC

Principali Notizie su Eventi

EU Finance Ministers Tally Economic Hit of Iran War -- Update

28 mar 2026, 13:32 UTC

Utili

Berkshire Hathaway Just Notched an 8-Day Losing Streak. It's a Good Time to Get Exposure to the Conglomerate. -- Barrons.com

28 mar 2026, 08:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

28 mar 2026, 08:00 UTC

Utili

It Was a Busy Week for Videogames. Keep An Eye on These Stocks. -- Barrons.com

27 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

27 mar 2026, 19:16 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Oil Futures Rise On Uncertainty Ahead of Weekend -- Market Talk

27 mar 2026, 19:07 UTC

Discorsi di Mercato

U.S. Natural Gas Gains As April Contract Expires -- Market Talk

27 mar 2026, 19:04 UTC

Discorsi di Mercato

Gold Rises But Can't Finish the Week Positive -- Market Talk

27 mar 2026, 19:03 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 19:02 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Among Central Banks, Canada Has Room to Handle Oil Inflation -- Market Talk

27 mar 2026, 18:12 UTC

Discorsi di Mercato

Foreign Fuels and Feedstocks to Get RINs Until 2028 -- Market Talk

27 mar 2026, 17:36 UTC

Principali Notizie su Eventi

The Iran War and Oil Prices Bring Risk of Deeper Market Lows. There Are Echoes of 2008. -- Barrons.com

27 mar 2026, 17:34 UTC

Discorsi di Mercato

Acquisizioni, Fusioni, Takeovers

Delivery Hero Shares Bounce as Stake-Sale Report Whets Investor Appetites -- Market Talk

27 mar 2026, 17:29 UTC

Discorsi di Mercato

U.S. Oil Rig Count Falls By 5 to 409 -- Market Talk

27 mar 2026, 16:38 UTC

Discorsi di Mercato

Carnival's Outlook Assumes Oil Prices Will Come Down -- Market Talk

27 mar 2026, 16:32 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Chinese Exposure to Higher Energy Costs Seen as Limited -- Market Talk

27 mar 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

27 mar 2026, 15:43 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Hormuz Closure Sends Tanker Rates to Record Highs -- Market Talk

27 mar 2026, 15:25 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

27 mar 2026, 15:25 UTC

Discorsi di Mercato

Swiss Franc Dented by Rising European Yields, SNB Intervention Threats -- Market Talk

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin: Inflation Progress 'May Be at Risk of Stalling'

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin: Holding Rates Steady in March 'Felt Prudent'

27 mar 2026, 15:00 UTC

Principali Notizie su Eventi

Fed's Barkin Says Iran War Raising Economic Uncertainty

27 mar 2026, 14:36 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Rising Yields, Oil Prices Seen as Overreaction -- Market Talk

27 mar 2026, 14:26 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Treasury Yields Mixed as Iran Peace Deal Remains Elusive -- Market Talk

Confronto tra pari

Modifica del prezzo

Mirati Therapeutics Inc Previsione

Obiettivo di Prezzo

By TipRanks

-0.05% in calo

Previsioni per 12 mesi

Media 58.67 USD -0.05%

Alto 59 USD

Basso 58 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Mirati Therapeutics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

5 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 5 che hanno fornito valutazioni azionarie a Mirati Therapeutics Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

67 / 349 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

EBITDA

Utile operativo

Chi Siamo Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.